AGEN
Price
$0.68
Change
-$0.00 (-0.00%)
Updated
Feb 23, 6:59 PM EST
19 days until earnings call
NTLA
Price
$26.10
Change
-$1.08 (-3.97%)
Updated
Feb 23, 6:59 PM EST
68 days until earnings call
Ad is loading...

AGEN vs NTLA ᐉ Comparison: Which is Better to Invest?

Header iconAGEN vs NTLA Comparison
Open Charts AGEN vs NTLABanner chart's image
Agenus
Price$0.68
Change-$0.00 (-0.00%)
Volume$5.66M
CapitalizationN/A
Intellia Therapeutics
Price$26.10
Change-$1.08 (-3.97%)
Volume$1.2M
CapitalizationN/A
View a ticker or compare two or three
AGEN vs NTLA Comparison Chart

Loading...

AGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NTLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AGEN vs. NTLA commentary
Feb 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a StrongSell and NTLA is a StrongSell.

COMPARISON
Comparison
Feb 24, 2024
Stock price -- (AGEN: $0.68 vs. NTLA: $26.10)
Brand notoriety: AGEN and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 66% vs. NTLA: 145%
Market capitalization -- AGEN: $260.22M vs. NTLA: $2.51B
AGEN [@Biotechnology] is valued at $260.22M. NTLA’s [@Biotechnology] market capitalization is $2.51B. The market cap for tickers in the [@Biotechnology] industry ranges from $552.93B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than AGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 3 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 5 bearish.
  • NTLA’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, AGEN is a better buy in the short-term than NTLA.

Price Growth

AGEN (@Biotechnology) experienced а +4.12% price change this week, while NTLA (@Biotechnology) price change was -5.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +38.88%.

Reported Earning Dates

AGEN is expected to report earnings on May 09, 2024.

NTLA is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AGEN with price predictions.
OPEN
A.I.dvisor published
a Summary for NTLA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
NTLA($2.51B) has a higher market cap than AGEN($260M). NTLA YTD gains are higher at: -14.398 vs. AGEN (-17.611). AGEN has higher annual earnings (EBITDA): -201.61M vs. NTLA (-476.94M). NTLA has more cash in the bank: 855M vs. AGEN (106M). AGEN has less debt than NTLA: AGEN (89M) vs NTLA (118M). AGEN has higher revenues than NTLA: AGEN (101M) vs NTLA (51.8M).
AGENNTLAAGEN / NTLA
Capitalization260M2.51B10%
EBITDA-201.61M-476.94M42%
Gain YTD-17.611-14.398122%
P/E Ratio12.89N/A-
Revenue101M51.8M195%
Total Cash106M855M12%
Total Debt89M118M75%
FUNDAMENTALS RATINGS
AGEN vs NTLA: Fundamental Ratings
AGEN
NTLA
OUTLOOK RATING
1..100
214
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
48
Fair valued
PROFIT vs RISK RATING
1..100
10088
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
6363
P/E GROWTH RATING
1..100
65100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (48) in the Biotechnology industry is somewhat better than the same rating for AGEN (96). This means that NTLA’s stock grew somewhat faster than AGEN’s over the last 12 months.

NTLA's Profit vs Risk Rating (88) in the Biotechnology industry is in the same range as AGEN (100). This means that NTLA’s stock grew similarly to AGEN’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as AGEN (100). This means that NTLA’s stock grew similarly to AGEN’s over the last 12 months.

NTLA's Price Growth Rating (63) in the Biotechnology industry is in the same range as AGEN (63). This means that NTLA’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's P/E Growth Rating (65) in the Biotechnology industry is somewhat better than the same rating for NTLA (100). This means that AGEN’s stock grew somewhat faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENNTLA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bearish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
87%
View a ticker or compare two or three
Ad is loading...
AGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
NTLADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CSARX12.490.01
+0.08%
Columbia Global Opportunities R
RWIFX63.000.04
+0.06%
American Funds Capital World Gr&Inc R5
CHTYX18.370.01
+0.05%
Invesco Charter Y
DGLRX22.13N/A
N/A
BNY Mellon Global Stock - I
CAMZX15.80-0.03
-0.19%
Cambiar Small Cap Instl

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
+1.05%
CRSP - AGEN
49%
Loosely correlated
-2.55%
NTLA - AGEN
45%
Loosely correlated
-3.97%
AXON - AGEN
42%
Loosely correlated
-0.34%
INVA - AGEN
40%
Loosely correlated
N/A
AKRO - AGEN
39%
Loosely correlated
+4.67%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with BEAM. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-3.97%
BEAM - NTLA
77%
Closely correlated
+1.46%
VCYT - NTLA
71%
Closely correlated
-8.87%
EDIT - NTLA
70%
Closely correlated
-1.45%
DNLI - NTLA
68%
Closely correlated
+0.59%
DNA - NTLA
61%
Loosely correlated
N/A
More